Table 5.
Univariate analysis of serological features in successful and adverse pregnancy outcome (APO) pregnancies.
| Clinical/serological features | APO (n = 50) (17.7%) | Successful pregnancies (n = 233) (82.3%) | p-Value | OR (CI 95%) |
|---|---|---|---|---|
| Lupus anticoagulant (LA) positivity (n = 125) | 29/50 (58) | 96/233 (41.2) | 0.03c | 1.97 (1.01–3.83) |
| LA single positivity (n = 20) | 2/50 (4) | 18/233 (7) | NS | – |
| IgG anticardiolipin (aCL) (n = 153) | 36/50 (72) | 117/233 (50.2) | 0.005c | 2.54 (1.25–5.26) |
| IgG aCL single positivity (n = 37) | 8/50 (16) | 29/233 (12.4) | NS | |
| IgM aCL (n = 53) | 13/50 (26) | 40/233 (17.2) | NS | – |
| IgM aCL single positivity (n = 6) | 1/50 (2) | 5/233 (2.1) | NS | – |
| IgG anti-B2GPI (n = 134) | 22/50 (44) | 112/233 (48.1) | NS | – |
| IgG anti-B2GPI single positivity (n = 36) | 4/50 (8) | 32/233 (13.7) | NS | |
| IgM anti-β2GPI positivity (n = 107) | 17/50 (34) | 90/233 (38.6) | NS | – |
| IgM anti-B2GPI single positivity (n = 24) | 2/50 (4) | 22/233 (9.4) | NS | – |
| Single aPL positivity (n = 144) | 20/50 (40) | 124/233 (53.2) | NS | – |
| Double aPL positivity (n = 55) | 8/50 (16) | 47/233 (21) | NS | – |
| Triple aPL positivity (n = 84) | 22/50 (44) | 62/233 (26.6) | 0.015c | 2.16 (1.10–4.25) |
| Other autoantibodiesa (n = 78) | 21/50 (42) | 57/233 (24.5) | 0.012c | 2.23 (1.12–4.42) |
| Low complement levelsb (data available for 195 pregnancies) (n = 27) | 11/34 (32.3) | 16/161 (9.9) | 0.001d | 4.33 (1.63–11.46) |
aOther autoantibodies, antinuclear antibody ≥1:320, anti-double-stranded DNA, antibodies to extractable nuclear antigens.
bLow complement levels, decrease in C3 and/or C4 at conception or during first trimester.
NS, not statistically significant.
cNot significant at multivariate analysis.
dSignificant at multivariate analysis, p = 0.02 (OR 2.3, CI 95% 1.17–9.15).